ARCHIVES

More Cost-Effective To Use Cetuximab In Patients With Wild-Type KRAS Gene

This article is from The Cancer Letter archive.

Vol. 32 No. 8 | August 28, 2009

Download PDF Visit The Full Archive

Related Articles

“Forward Funding” Will Cost NCI $38 Million, 270 Grants, As OMB Legally Impounds FY 1985 Money

February 1, 1985

NCI-Approved Clinical Trials

December 31, 2004

60 Minutes To Air Segment On The “Deception at Duke”

February 10, 2012

NCS Group Asks DRG Adjustments For Institutions With Peer reviewed Components, 25 Protocol Patients

July 1, 1983

American Radium Society Abstracts

July 23, 1976

NCI Plans $40M In Grants For Cancer Outcomes Studies.

June 30, 2000